HCPCS Level II code J0881 denotes an injection of darbepoetin alfa, 1 microgram, for non-ESRD indications. As an erythropoiesis-stimulating agent used to manage anemia in patients with chronic disease or receiving certain cancer treatments, this code captures pharmacy-administered biologic therapy delivered in outpatient settings. Nationally, use of ESAs affects clinical workflows, drug acquisition costs, and payer coverage policies due to safety considerations and bundled payment arrangements.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for ESA use, payer coverage patterns, common billing considerations for administration in outpatient infusion centers and physician offices, and benchmarking elements when available. The publication summarizes typical sites of service, payer scope, and operational implications for billing and claims processing. Data not available in the input for specific modifiers, associated taxonomies, ICD-10 diagnoses, or related codes are noted as missing and are not included.